The National Nanotechnology Coordination Office schedules a June 11-12, 2013, public workshop in Washington, D.C., “to obtain input from stakeholders regarding the goals and objectives of an updated U.S. National Nanotechnology Initiative (NNI) Strategic Plan that is currently under development and scheduled for completion by December 2013.” Registration is limited; it will open May 1 and close June 3 or when capacity is reached. Comments are requested by May 13.

The U.S. Patent and Trademark Office (USPTO) invites public comment on a continuing information collection for which it has estimated time and expense burdens. The collection pertains to information USPTO needs to review when deciding whether to loosen or rescind limitations on the disclosure of information contained in patents and patent applications subject to secrecy orders because they involve inventions deemed by the federal government “to be detrimental to national security.” The collection also relates to petitions for a foreign filing license for those seeking to file applications for patents in foreign countries. Comments are requested by June 24, 2013.

The Food and Drug Administration (FDA) issues draft guidance titled “Use of International Standard ISO-10993, ‘Biological Evaluation of Medical Devices Part 1: Evaluation and Testing.’” The document is intended to help industry prepare premarket applications, humanitarian device exemptions, investigational device applications, premarket notifications, and “de novo requests for medical devices that come into contact with the human body in order to determine the potential toxicity resulting from contact of the component materials of the device with the body.” Comments are requested by July 22, 2013.

The Food and Drug Administration makes available draft guidance for industry titled “Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors.” “The draft guidance provides sponsors of new drug applications (NDAs), biologics licensing applications (BLAs), abbreviated new drug applications (ANDAs), and prescription drugs marketed without an approved NDA or ANDA with a set of principles and recommendations for ensuring that critical elements of product container labels and carton labeling are designed to promote safe dispensing, administration, and use of the product to minimize medication errors.” Comments are requested by June 24, 2013.